Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma

Clinical Trial ID NCT00471887

Rank	Title	Journal	Year	PubWeight™‹?›
1	Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.	Sci Transl Med	2014	2.50
2	CTLA-4 blockade in tumor models: an overview of preclinical and translational research.	Cancer Immun	2013	1.71
3	CTLA4 blockade broadens the peripheral T-cell receptor repertoire.	Clin Cancer Res	2014	1.66
4	Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.	Eur J Cancer	2015	1.53
5	CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.	Clin Cancer Res	2011	1.42
6	CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.	J Transl Med	2009	1.28
7	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.	J Hematol Oncol	2016	1.12
8	Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma.	PLoS One	2010	1.09
9	Natural killer T cells in advanced melanoma patients treated with tremelimumab.	PLoS One	2013	0.83
10	Targeting CD8+ T-cell tolerance for cancer immunotherapy.	Immunotherapy	2014	0.81
11	Tremelimumab.	Drugs R D	2010	0.75